England’s health technology assessment body, NICE, has issued final guidance recommending the use of GW Pharmaceuticals’ Epidyolex (cannabidiol/CBD) for seizures associated with two rare conditions, Lennox-Gastaut syndrome and Dravet’s syndrome. In doing so, NICE has reversed its earlier advice against using the drug on the National Health Service for these indications.
NICE has also changed its stance on GW’s Sativex spray (cannabidiol plus tetrahydrocannabinol), and is now recommending its use in...








